Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bictegravir concentrations and antiviral activity in cerebrospinal fluid in HIV-1 Infected individuals

Next Previous
Trial Profile

Bictegravir concentrations and antiviral activity in cerebrospinal fluid in HIV-1 Infected individuals

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms BICS

    • Most Recent Events

    • 22 Nov 2018 Status changed from recruiting to completed.
    • 26 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top